Skip to search formSkip to main contentSkip to account menu

WX-671

Known as: Serine Protease Inhibitor WX-671 
An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

upamostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.
4060 Background: WX-671 (Mesupron) is an orally available prodrug of WX-UK1, a serine protease inhibitor that inhibits uPA as… 
Review
2010
Review
2010
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Pancreatic cancer is the 4th leading cancer cause mortality in both men and women. Pancreatic cancer is usually diagnosed in the… 
2006
2006
A Phase I pharmacokinetic (PK) study of single dose oral therapy with a uPA inhibitor (WX-671).
13091 Background: WX-671 is an orally available prodrug of WX-UK1, a serine protease inhibitor that inhibits uPA as well as other… 
2005
2005
AZD2171, an orally active inhibitor of VEGFR tyrosine kinase activity, reduces polyp burden in a mouse model of intestinal cancer
5841 AZD2171 is a novel, highly potent and orally active inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)